Well BTD is a big deal if we are talking money and
Post# of 155596
For example SNPX is funded by the NIH for
Alzheimer’s, which helped them get through their latest trial without burning too much cash.
So yes as Evil pointed out we continue to de-risk as we get data from other trials or other big news like BTD.
Many companies will dilute share holders right after a price spike and a PR like BTD. That’s also a common way to get money for future trials.
Now as far as dilution, we already have a ton of shares out at this point. Too many IMO. The last thing shareholders want is more dilution. NP is fully aware of this and that’s why he prides himself on it. I give him credit where it’s due. Maybe someday the company will buy back shares making this float smaller.


CytoDyn Inc (CYDY) Stock Research Links
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com